{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:04:29Z","timestamp":1779674669716,"version":"3.53.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7242230"],"award-info":[{"award-number":["7242230"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04947-9","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:18:04Z","timestamp":1775560684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidimensional single-cell analysis of the molecular characteristics and functional pathways of Regulatory T cells in the microenvironment of HR+ breast cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Peiying","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"10286","key":"4947_CR1","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)32381-3.","journal-title":"Lancet"},{"key":"4947_CR2","unstructured":"SEER*Explorer, National Cancer Institute. An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program. 2025 Jul 2. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"issue":"3","key":"4947_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: a Review. JAMA. 2019;321(3):288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323.","journal-title":"JAMA"},{"issue":"1","key":"4947_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/GCO.0000000000000925","volume":"36","author":"NV Baclig","year":"2024","unstructured":"Baclig NV, McCann KE. Updates in the treatment of HR+HER2- breast cancer. Curr Opin Obstet Gynecol. 2024;36(1):57\u201363. https:\/\/doi.org\/10.1097\/GCO.0000000000000925.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"7","key":"4947_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523\u201332. https:\/\/doi.org\/10.1038\/nri2343.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"4947_CR6","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/modpathol.2008.160","volume":"21","author":"SD Bohling","year":"2008","unstructured":"Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol. 2008;21(12):1527\u201332. https:\/\/doi.org\/10.1038\/modpathol.2008.160.","journal-title":"Mod Pathol"},{"issue":"7","key":"4947_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","volume":"10","author":"S Sakaguchi","year":"2010","unstructured":"Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3\u2009+\u2009regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490\u2013500. https:\/\/doi.org\/10.1038\/nri2785.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"4947_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41587-020-0469-4","volume":"38","author":"E Mereu","year":"2020","unstructured":"Mereu E, Lafzi A, Moutinho C, Ziegenhain C, McCarthy DJ, \u00c1lvarez-Varela A. Benchmarking single-cell RNA-sequencing protocols for cell atlas projects. Nat Biotechnol. 2020;38(6):747\u201355. https:\/\/doi.org\/10.1038\/s41587-020-0469-4.","journal-title":"Nat Biotechnol"},{"key":"4947_CR9","doi-asserted-by":"publisher","unstructured":"Wolde T, Bhardwaj V, Pandey V. Current Bioinformatics Tools in Precision Oncology. MedComm (2020). 2025;6(7):e70243. Published 2025 Jul 9. https:\/\/doi.org\/10.1002\/mco2.70243","DOI":"10.1002\/mco2.70243"},{"issue":"1","key":"4947_CR10","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11(1):6322. https:\/\/doi.org\/10.1038\/s41467-020-20059-6.","journal-title":"Nat Commun"},{"issue":"9","key":"4947_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41422-020-0355-0","volume":"30","author":"J Qian","year":"2020","unstructured":"Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 2020;30(9):745\u201362. https:\/\/doi.org\/10.1038\/s41422-020-0355-0.","journal-title":"Cell Res"},{"issue":"9","key":"4947_CR12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53(9):1334\u201347. https:\/\/doi.org\/10.1038\/s41588-021-00911-1.","journal-title":"Nat Genet"},{"issue":"5","key":"4947_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell. 2018;174(5):1293\u2013e130836. https:\/\/doi.org\/10.1016\/j.cell.2018.05.060.","journal-title":"Cell"},{"issue":"10","key":"4947_CR14","doi-asserted-by":"publisher","first-page":"e2204951","DOI":"10.1002\/advs.202204951","volume":"10","author":"J Qiu","year":"2023","unstructured":"Qiu J, Qu X, Wang Y, Guo C, Lv B, Jiang Q. Single-Cell Landscape Highlights Heterogenous Microenvironment, Novel Immune Reaction Patterns, Potential Biomarkers and Unique Therapeutic Strategies of Cervical Squamous Carcinoma, Human Papillomavirus-Associated (HPVA) and Non-HPVA Adenocarcinoma. Adv Sci (Weinh). 2023;10(10):e2204951. https:\/\/doi.org\/10.1002\/advs.202204951.","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"4947_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","volume":"29","author":"Y Chu","year":"2023","unstructured":"Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023;29(6):1550\u201362. https:\/\/doi.org\/10.1038\/s41591-023-02371-y.","journal-title":"Nat Med"},{"issue":"4","key":"4947_CR16","doi-asserted-by":"publisher","first-page":"e126464","DOI":"10.1172\/jci.insight.126464","volume":"4","author":"X Fang","year":"2019","unstructured":"Fang X, Bogomolovas J, Trexler C, Chen J. The BAG3-dependent and -independent roles of cardiac small heat shock proteins. JCI Insight. 2019;4(4):e126464. https:\/\/doi.org\/10.1172\/jci.insight.126464.","journal-title":"JCI Insight"},{"issue":"6","key":"4947_CR17","doi-asserted-by":"publisher","first-page":"106158","DOI":"10.1016\/j.jinf.2024.106158","volume":"88","author":"Z Wen","year":"2024","unstructured":"Wen Z, Wang L, Ma H, Li L, Wan L, Shi L, Li H, Chen H, Hao W, Song S, Xue Q, Wei Y, Li F, Xu J, Zhang S, Wong KW, Song Y. Integrated single-cell transcriptome and T cell receptor profiling reveals defects of T cell exhaustion in pulmonary tuberculosis. J Infect. 2024;88(6):106158. https:\/\/doi.org\/10.1016\/j.jinf.2024.106158.","journal-title":"J Infect"},{"issue":"5","key":"4947_CR18","doi-asserted-by":"publisher","first-page":"e008983","DOI":"10.1136\/jitc-2024-008983","volume":"12","author":"Z Wang","year":"2024","unstructured":"Wang Z, Ji X, Zhang Y, Yang F, Su H, Zhang H, Li Z, Zhang W, Sun W. Interactions between LAMP3\u2009+\u2009dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma. J Immunother Cancer. 2024;12(5):e008983. https:\/\/doi.org\/10.1136\/jitc-2024-008983.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4947_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cac2.12429","volume":"43","author":"S Ding","year":"2023","unstructured":"Ding S, Qiao N, Zhu Q, Tong Y, Wang S, Chen X. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer. Cancer Commun (Lond). 2023;43(6):661\u201384. https:\/\/doi.org\/10.1002\/cac2.12429.","journal-title":"Cancer Commun (Lond)"},{"issue":"11","key":"4947_CR20","doi-asserted-by":"publisher","first-page":"e107333","DOI":"10.15252\/embj.2020107333","volume":"40","author":"B Pal","year":"2021","unstructured":"Pal B, Chen Y, Vaillant F, Capaldo BD, Joyce R, Song X. A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. EMBO J. 2021;40(11):e107333. https:\/\/doi.org\/10.15252\/embj.2020107333.","journal-title":"EMBO J"},{"issue":"6","key":"4947_CR21","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.immuni.2014.12.007","volume":"41","author":"JM Schenkel","year":"2014","unstructured":"Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity. 2014;41(6):886\u201397.","journal-title":"Immunity"},{"issue":"5","key":"4947_CR22","doi-asserted-by":"publisher","first-page":"101511","DOI":"10.1016\/j.xcrm.2024.101511","volume":"5","author":"L Xu","year":"2024","unstructured":"Xu L, Saunders K, Huang SP, Knutsdottir H, Martinez-Algarin K, Terrazas I. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Rep Med. 2024;5(5):101511. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101511.","journal-title":"Cell Rep Med"},{"key":"4947_CR23","doi-asserted-by":"publisher","first-page":"868813","DOI":"10.3389\/fimmu.2022.868813","volume":"13","author":"Z Tan","year":"2022","unstructured":"Tan Z, Kan C, Sun M, Yang F, Wong M, Wang S. Mapping Breast Cancer Microenvironment Through Single-Cell Omics. Front Immunol. 2022;13:868813. https:\/\/doi.org\/10.3389\/fimmu.2022.868813.","journal-title":"Front Immunol"},{"issue":"5","key":"4947_CR24","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1182\/blood-2005-01-0206","volume":"106","author":"JJ Zaunders","year":"2005","unstructured":"Zaunders JJ, Munier ML, Kaufmann DE, Ip S, Grey P, Smith D. Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection. Blood. 2005;106(5):1660\u20137. https:\/\/doi.org\/10.1182\/blood-2005-01-0206.","journal-title":"Blood"},{"issue":"5","key":"4947_CR25","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1172\/jci97454","volume":"128","author":"AB Khan","year":"2018","unstructured":"Khan AB, Carpenter B, Santos E, Sousa P, et al. Redirection to the bone marrow improves T cell persistence and antitumor functions. J Clin Invest. 2018;128(5):2010\u201324. https:\/\/doi.org\/10.1172\/jci97454.","journal-title":"J Clin Invest"},{"issue":"4","key":"4947_CR26","doi-asserted-by":"publisher","first-page":"e46620","DOI":"10.15252\/embr.201846620","volume":"20","author":"JP Hewitson","year":"2019","unstructured":"Hewitson JP, Shah KM, Brown N, et al. miR-132 suppresses transcription of ribosomal proteins to promote protective Th1 immunity. EMBO Rep. 2019;20(4):e46620. https:\/\/doi.org\/10.15252\/embr.201846620.","journal-title":"EMBO Rep"},{"issue":"10","key":"4947_CR27","doi-asserted-by":"publisher","first-page":"116412","DOI":"10.1016\/j.celrep.2025.116412","volume":"44","author":"A Galloway","year":"2025","unstructured":"Galloway A, Knop K, Gomez-Moreira C, Xavier V, Thomson S, Yoshikawa H. CMTR1 directs mitochondrial dynamics during T cell activation through epitranscriptomic regulation of splice isoforms. Cell Rep. 2025;44(10):116412. https:\/\/pubmed.ncbi.nlm.nih.gov\/41091598\/.","journal-title":"Cell Rep"},{"issue":"5","key":"4947_CR28","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1002\/imt2.238","volume":"3","author":"D Chen","year":"2024","unstructured":"Chen D, Xu L, Xing H, Shen W, Song Z, Li H. Sangerbox 2: Enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platform. Imeta. 2024;3(5):e238. https:\/\/doi.org\/10.1002\/imt2.238.","journal-title":"Imeta"},{"issue":"1","key":"4947_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12(1):1088. https:\/\/doi.org\/10.1038\/s41467-021-21246-9.","journal-title":"Nat Commun"},{"issue":"6","key":"4947_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41576-021-00444-7","volume":"23","author":"J Ding","year":"2022","unstructured":"Ding J, Sharon N, Bar-Joseph Z. Temporal modelling using single-cell transcriptomics. Nat Rev Genet. 2022;23(6):355\u201368. https:\/\/doi.org\/10.1038\/s41576-021-00444-7.","journal-title":"Nat Rev Genet"},{"key":"4947_CR31","doi-asserted-by":"publisher","first-page":"175883592412824","DOI":"10.1177\/17588359241282499","volume":"16","author":"S Wu","year":"2024","unstructured":"Wu S, Xu J, Ma Y, Liang G, Wang J, Sun T. Advances in the mechanism of CDK4\/6 inhibitor resistance in HR+\/HER2- breast cancer. Ther Adv Med Oncol. 2024;16:17588359241282499. https:\/\/doi.org\/10.1177\/17588359241282499.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"4947_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","volume":"126","author":"SK Herzog","year":"2022","unstructured":"Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126(2):174\u201386. https:\/\/doi.org\/10.1038\/s41416-021-01564-x.","journal-title":"Br J Cancer"},{"issue":"8","key":"4947_CR33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2217\/fon-2021-0668","volume":"18","author":"S Lopez-Tarruella","year":"2022","unstructured":"Lopez-Tarruella S, Echavarria I, Jerez Y, Herrero B, Gamez S, Martin M. How we treat HR-positive, HER2-negative early breast cancer. Future Oncol. 2022;18(8):1003\u201322. https:\/\/doi.org\/10.2217\/fon-2021-0668.","journal-title":"Future Oncol"},{"issue":"34","key":"4947_CR34","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","volume":"24","author":"GJ Bates","year":"2006","unstructured":"Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373\u201380. https:\/\/doi.org\/10.1200\/JCO.2006.05.9584.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4947_CR35","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775\u201387. https:\/\/doi.org\/10.1016\/j.cell.2008.05.009.","journal-title":"Cell"},{"issue":"19","key":"4947_CR36","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.3390\/cancers17193172","volume":"17","author":"A Xu","year":"2025","unstructured":"Xu A, Ayoub S, Zhang H, Wu Y, Rau M, Ma X. Regulatory T Cells in Invasive Breast Cancer: prognosis, Mechanisms and Therapy. Cancers (Basel). 2025;17(19):3172. https:\/\/doi.org\/10.3390\/cancers17193172.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4947_CR37","doi-asserted-by":"publisher","first-page":"e23154","DOI":"10.4161\/jkst.23154","volume":"2","author":"SA Mahmud","year":"2013","unstructured":"Mahmud SA, Manlove LS, Farrar MA. Interleukin-2 and STAT5 in regulatory T cell development and function. JAKSTAT. 2013;2(1):e23154. https:\/\/doi.org\/10.4161\/jkst.23154.","journal-title":"JAKSTAT"},{"issue":"1","key":"4947_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4049\/jimmunol.178.1.280","volume":"178","author":"MA Burchill","year":"2007","unstructured":"Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3\u2009+\u2009regulatory T cells. J Immunol. 2007;178(1):280\u201390. https:\/\/doi.org\/10.4049\/jimmunol.178.1.280.","journal-title":"J Immunol"},{"issue":"1","key":"4947_CR39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41698-025-01041-1","volume":"9","author":"NM Kettner","year":"2025","unstructured":"Kettner NM, Bui TN, Navarro-Yepes J, Ghotbaldini S, Quintela B, Luo CK. IL-6 predicts CDK4\/6 inhibitor resistance, identifying STAT3 as a target in HR + \/HER2-negative metastatic breast cancer. NPJ Precis Oncol. 2025;9(1):260. https:\/\/doi.org\/10.1038\/s41698-025-01041-1.","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"4947_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4947_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4048\/jbc.2013.16.1.40","volume":"16","author":"Y Chen","year":"2013","unstructured":"Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q. STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer. J Breast Cancer. 2013;16(1):40\u20139. https:\/\/doi.org\/10.4048\/jbc.2013.16.1.40.","journal-title":"J Breast Cancer"},{"issue":"11","key":"4947_CR42","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798\u2013809. https:\/\/doi.org\/10.1038\/nrc2734.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"4947_CR43","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm1325","volume":"11","author":"M Kortylewski","year":"2005","unstructured":"Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11(12):1314\u201321. https:\/\/doi.org\/10.1038\/nm1325.","journal-title":"Nat Med"},{"issue":"11","key":"4947_CR44","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nri1226","volume":"3","author":"K Shuai","year":"2003","unstructured":"Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3(11):900\u201311. https:\/\/doi.org\/10.1038\/nri1226.","journal-title":"Nat Rev Immunol"},{"key":"4947_CR45","doi-asserted-by":"publisher","unstructured":"Owen KL, Brockwell NK, Parker BS, JAK-STAT Signaling. A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers (Basel). 2019;11(12):2002. https:\/\/doi.org\/10.3390\/cancers11122002.","DOI":"10.3390\/cancers11122002"},{"issue":"1","key":"4947_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4947_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nri1995","volume":"7","author":"H Yu","year":"2007","unstructured":"Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41\u201351. https:\/\/doi.org\/10.1038\/nri1995.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4947_CR48","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri1703","volume":"5","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749\u201359. https:\/\/doi.org\/10.1038\/nri1703.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4947_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33\u201340. https:\/\/doi.org\/10.1038\/nrd2781.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"4947_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/wsbm.1331","volume":"8","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, Vargas J, Hoffmann A. Signaling via the NF\u03baB system. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):227\u201341. https:\/\/doi.org\/10.1002\/wsbm.1331. Epub 2016 Mar 16.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"4","key":"4947_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccr.2009.02.015","volume":"15","author":"H Lee","year":"2009","unstructured":"Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15(4):283\u201393. https:\/\/doi.org\/10.1016\/j.ccr.2009.02.015.","journal-title":"Cancer Cell"},{"issue":"3","key":"4947_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.smim.2014.05.004","volume":"26","author":"MS Hayden","year":"2014","unstructured":"Hayden MS, Ghosh S. Regulation of NF-\u03baB by TNF family cytokines. Semin Immunol. 2014;26(3):253\u201366. https:\/\/doi.org\/10.1016\/j.smim.2014.05.004.","journal-title":"Semin Immunol"},{"issue":"1","key":"4947_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.171.1.35","volume":"171","author":"AN Shakhov","year":"1990","unstructured":"Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med. 1990;171(1):35\u201347. https:\/\/doi.org\/10.1084\/jem.171.1.35.","journal-title":"J Exp Med"},{"issue":"2","key":"4947_CR54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14740\/wjon2532","volume":"16","author":"N Qodir","year":"2025","unstructured":"Qodir N, Pramudhito D, Legiran; Hafy Z, Iman MB, Syafira F. Tumor Necrosis Factor-Alpha and Its Association With Breast Cancer: a Systematic Review. World J Oncol. 2025;16(2):143\u201351. https:\/\/doi.org\/10.14740\/wjon2532.","journal-title":"World J Oncol"},{"key":"4947_CR55","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fonc.2020.00584","volume":"10","author":"MF Mercogliano","year":"2020","unstructured":"Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor Necrosis Factor \u03b1 Blockade: an Opportunity to Tackle Breast Cancer. Front Oncol. 2020;10:584. https:\/\/doi.org\/10.3389\/fonc.2020.00584.","journal-title":"Front Oncol"},{"issue":"1","key":"4947_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-019-00489-1","volume":"43","author":"D Cruceriu","year":"2020","unstructured":"Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr). 2020;43(1):1\u201318. https:\/\/doi.org\/10.1007\/s13402-019-00489-1.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"4947_CR57","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4947_CR58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","volume":"44","author":"S Imani","year":"2025","unstructured":"Imani S, Farghadani R, Roozitalab G, Maghsoudloo M, Emadi M, Moradi A. Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy. J Exp Clin Cancer Res. 2025;44(1):131. https:\/\/doi.org\/10.1186\/s13046-025-03394-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"13","key":"4947_CR59","doi-asserted-by":"publisher","first-page":"7208","DOI":"10.3390\/ijms25137208","volume":"25","author":"L Yang","year":"2024","unstructured":"Yang L, Hu Q, Huang T. Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: how to Convert Cold Tumors to Hot Tumors. Int J Mol Sci. 2024;25(13):7208. https:\/\/doi.org\/10.3390\/ijms25137208.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4947_CR60","doi-asserted-by":"publisher","first-page":"X1","DOI":"10.1530\/ERC-16-0404e","volume":"24","author":"AMK Law","year":"2017","unstructured":"Law AMK, Lim E, Ormandy CJ, Gallego-Ortega D. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocr Relat Cancer. 2017;24(7):X1. https:\/\/doi.org\/10.1530\/ERC-16-0404e.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4947_CR61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-021-06337-x","volume":"190","author":"A Hanna","year":"2021","unstructured":"Hanna A, Balko JM. Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Res Treat. 2021;190(1):5\u201317. https:\/\/doi.org\/10.1007\/s10549-021-06337-x.","journal-title":"Breast Cancer Res Treat"},{"key":"4947_CR62","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.18632\/oncotarget.28303","volume":"13","author":"M Shibata","year":"2022","unstructured":"Shibata M, Nanno K, Yoshimori D, Nakajima T, Takada M, Yazawa T. Myeloid-derived suppressor cells: cancer, autoimmune diseases, and more. Oncotarget. 2022;13:1273\u201385. https:\/\/doi.org\/10.18632\/oncotarget.28303.","journal-title":"Oncotarget"},{"key":"4947_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-3-030-34461-0_18","volume":"1232","author":"G Multhoff","year":"2020","unstructured":"Multhoff G, Vaupel P. Hypoxia Compromises Anti-Cancer Immune Responses. Adv Exp Med Biol. 2020;1232:131\u201343. https:\/\/doi.org\/10.1007\/978-3-030-34461-0_18.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"4947_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41523-025-00776-1","volume":"11","author":"X Sun","year":"2025","unstructured":"Sun X, Axelrod ML, Waks AG, Fu J, DiLullo M, Van Allen EM. Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients. NPJ Breast Cancer. 2025;11(1):65. https:\/\/doi.org\/10.1038\/s41523-025-00776-1.","journal-title":"NPJ Breast Cancer"},{"issue":"18","key":"4947_CR65","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-24-1286","volume":"30","author":"X Sun","year":"2024","unstructured":"Sun X, Kennedy LC, Gonzalez-Ericsson PI, Sanchez V, Sanders M, Perou CM. Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort. Clin Cancer Res. 2024;30(18):4077\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1286.","journal-title":"Clin Cancer Res"},{"key":"4947_CR66","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568. https:\/\/doi.org\/10.3389\/fimmu.2021.636568.","journal-title":"Front Immunol"},{"issue":"1","key":"4947_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jir.2014.0026","volume":"35","author":"M Esquivel-Vel\u00e1zquez","year":"2015","unstructured":"Esquivel-Vel\u00e1zquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015;35(1):1\u201316. https:\/\/doi.org\/10.1089\/jir.2014.0026.","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"4947_CR68","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3892\/ijo.2015.3185","volume":"47","author":"V Richard","year":"2015","unstructured":"Richard V, Kindt N, Saussez S. Macrophage migration inhibitory factor involvement in breast cancer (Review). Int J Oncol. 2015;47(5):1627\u201333. https:\/\/doi.org\/10.3892\/ijo.2015.3185.","journal-title":"Int J Oncol"},{"key":"4947_CR69","doi-asserted-by":"publisher","first-page":"114822","DOI":"10.1016\/j.biopha.2023.114822","volume":"163","author":"E Pavitra","year":"2023","unstructured":"Pavitra E, Kancharla J, Gupta VK, Prasad K, Sung JY, Kim J. The role of NF-\u03baB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy. Biomed Pharmacother. 2023;163:114822. https:\/\/doi.org\/10.1016\/j.biopha.2023.114822.","journal-title":"Biomed Pharmacother"},{"key":"4947_CR70","doi-asserted-by":"publisher","first-page":"10568","DOI":"10.3389\/or.2022.10568","volume":"16","author":"M Devanaboyina","year":"2022","unstructured":"Devanaboyina M, Kaur J, Whiteley E, Lin L, Einloth K, Morand S. NF-\u03baB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer. Oncol Rev. 2022;16:10568. https:\/\/doi.org\/10.3389\/or.2022.10568.","journal-title":"Oncol Rev"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04947-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:59:55Z","timestamp":1779674395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04947-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4947"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04947-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized publicly available datasets from the Gene Expression Omnibus (GEO) database (accession numbers: GSE228499 and GSE176078).This study does not involve ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"764"}}